T-DM1 Falls Short as Less-Toxic Option for Early Breast Cancer Promising efficacy but higher discontinuation rates and cost likely a deterrent Dec 13, 2019
Denosumab Use in Myeloma Soars for No Obvious Reason More expensive than competitor without being better, so why does it now have nearly half the market? Dec 12, 2019
Edging Closer to OS Benefit With Novel Anti-HER2 Drug Larger benefit with margetuximab in most common HER2 breast cancer phenotype Dec 12, 2019
New Standard for Metastatic HER2 Breast Cancer Consistent PFS, OS benefit with combination including oral HER2 inhibitor tucatinib Dec 11, 2019
Survival Bump With Oral AML Maintenance Ten-month OS gain, doubling of RFS with oral azacitidine in transplant-ineligible patients Dec 10, 2019
'Off-the-Shelf' Therapy Active After CAR T-Cell Failure Bispecific antibody mosunetuzumab targets CD3, CD20; needs no ex vivo T-cell processing Dec 07, 2019
Study Bolsters Case for Novel Xarelto Formulation for Kids Pharmacokinetic data indicate appropriate dosing schemes across wide range of weight categories Dec 07, 2019
Gene Therapy Hits Its Goal in BCG-Unresponsive NMIBC In phase III trial, 53% achieved complete response at 3 months Dec 06, 2019
Living Near Oil Refinery Tied to Greater Bladder Cancer Risk Past data support "biological plausibility" for link, says researcher Dec 06, 2019
Beta Blockers No Help in Advanced Prostate Cancer Findings question earlier retrospective data that pointed to possible survival benefit Dec 05, 2019
Docetaxel First May Boost Survival in mCRPC Superior outcomes observed versus approach where chemo follows newer agents Dec 05, 2019
Will Smith Vlogs His First Colonoscopy Actor hopes to bring awareness to important healthcare screening Dec 05, 2019
More Evidence That Aspirin Can Stave Off Death PLCO follow-up data support protective effect Dec 04, 2019
MRI-Guided Ultrasound Zaps Low-Risk Prostate Cancer TULSA devices achieves prostate volume reduction Dec 04, 2019
A Surgical First for Removal of an Appendiceal Neoplasm Technique deemed safe and feasible for selected patients and better than other minimally invasive approaches Nov 25, 2019
First-Line Combo Improves Survival in Advanced HCC Decreases in overall survival, progression-free survival hazards by almost 50% compared with sorafenib Nov 22, 2019
Study Suggests Viable Alternative to Mastectomy After In-Breast Recurrence Mastectomy rates low, good cancer control in selected patients Nov 21, 2019
Surgeon in Spotlight for Excising Soccer Ball-Sized Neck Tumor Called upon for expertise only 4 months into surgical career Nov 19, 2019
Metastatic Renal Cell Carcinoma: Watch for Brain Mets Present in roughly 5% of patients, survival worse in patients with larger or more lesions Nov 18, 2019
AHA Dedicates $20 Million to Youth Vaping Research Association and partners aim to "hold e-cigarette companies publicly accountable for their lies" Nov 16, 2019
Rheumatoid Arthritis Is No Bar to Cancer Immunotherapy Small study finds flares common with checkpoint inhibitors, but few patients stopped treatment because of them Nov 13, 2019
Results Mixed for At-Home HPV Testing Failed to show difference in clinical outcomes despite uptick in screening Nov 06, 2019
Why the Lower Risk of Prostate Cancer in Men With Diabetes? Findings from large cohort study do not support one leading hypothesis, researchers say Nov 06, 2019
Sex Assault at Mt. Sinai; Pharma's MD Millionaires; Mammography Marketing Machine This past week in healthcare investigations Oct 23, 2019
IGHV-Unmutated CLL: Gene Signature May Predict Outcomes After First-Line FCR Prognostic tool may predict who is likely to achieve a relatively long remission Oct 15, 2019
FCR Still an Option in IGHV-Unmutated CLL? Gene signature identifies lower-risk group with greater chemoimmunotherapy benefit Oct 08, 2019
First-Line Combo Boosts PFS in Untreated Bladder Cancer 'Clinically meaningful' trend in OS with atezolizumab-chemotherapy Oct 03, 2019
In Memory of Gerald Chodak, MD Pioneer of active surveillance for men with low-risk prostate cancer died last week Oct 03, 2019
New Standard in Third-Line Metastatic CRPC Cabazitaxel tops more anti-androgen in patients with "short-ish" response to abiraterone or enzalutamide Oct 01, 2019
Novel CDK 4/6 Inhibitor Fails in Triple Negative Breast Cancer Misses primary endpoints but has unexpected key benefit Oct 01, 2019
Neoadjuvant Anti-PD-1 Boosts pCR in TNBC Favorable trend toward improved event-free survival in preliminary analysis Sep 30, 2019
Trametinib Tx Shows Promise in Tough-to-Treat LGSOC Targeted drug provokes good response in chemoresistant, low-grade serous ovarian or peritoneal cancer Sep 30, 2019
Data Support 'Best Drug First' in EGFR-Mutant NSCLC Six-month survival gain with osimertinib, adding to PFS, safety advantages Sep 29, 2019
CDK 4/6 Inhibitors Boost OS in Advanced Breast Cancer Abemaciclib, ribociclib should become first-line treatment in HR-positive/HER2-negative disease, expert says Sep 29, 2019
PARP Inhibitors: The Key to a Tx Paradigm Shift in Ovarian Ca? PRIMA and VELIA trial findings advance niraparib and veliparib to the therapeutic front lines Sep 29, 2019
Abemaciclib Offers Hope in HR+/HER2+Breast Cancer Phase II monarcHER trial shows better PFS with abemaciclib-trastuzumab-fulvestrant Sep 29, 2019
First-Line Combo Boosts PFS in Advanced Ovarian Ca Olaparib-bevacizumab maintenance boosts PARP inhibitor benefits beyond BRCA-mutated subgroup Sep 28, 2019
Advanced HCC Trial Misses OS Endpoint But CheckMate 459 researchers tout "encouraging efficacy and favorable safety profile" Sep 28, 2019
